ALGENICS is a biopharmaceutical company leveraging a unique microalgae-based technology to produce recombinant therapeutics for animal and human health.
Microalgal cell lines engineered using our platform AlgebiosysTM are available under licensing agreement for production of glycosylated therapeutics with preferential applications in the field of monoclonal antibodies and viral subunits.
Our strategy is also to develop proprietary biotherapeutics for human use benefiting from our technology. Targets include recombinant products with enhanced biological activities for applications in oncology and virology.
